An Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder

Intramuscular olanzapine depot

Number of Participants With Adverse Events (AE)

Number of Participants With Treatment-Emergent Abnormal High Prolactin at Any Time Post Baseline

Number of Participants With Treatment-Emergent Abnormal High Alanine Transaminase (ALT), High Aspartate Transaminase (AST), High Total Bilirubin at Any Time Post Baseline

Number of Participants Having Normal Fasting Baseline Glucose Value With Treatment-Emergent High Fasting Glucose at Any Time Post Baseline

Number of Participants Having Normal Fasting Baseline Lipid Value With Treatment-Emergent High Fasting Lipid at Any Time Post Baseline

Change From Baseline in Weight at Month 76 Endpoint

Number of Participants With Potentially Clinically Significant (PCS) Weight Gain at Month 76 Endpoint

Number of Participants With Extrapyramidal Symptoms at Any Time

Number of Psychiatric Visits

Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Scores at Month 76 Endpoint

Change From Baseline in PANSS Positive Scores at Month 76 Endpoint

Change From Baseline in PANSS Negative Scores at Month 76 Endpoint

Change From Baseline in PANSS General Psychopathology Subscales at Month 76 Endpoint

Change From Baseline in Clinical Global Impression-Severity of Illness (CGI-S) Scores at Month 72 Endpoint

Change From Baseline in the Heinrichs-Carpenter Quality of Life Scale (QLS) Total Score at Month 76 Endpoint

Change From Baseline in 36-Item Short Form Health Survey (SF-36) at Month 76 Endpoint

Days of Hospitalization

Change From Baseline in the Subjective Well-Being Under Neuroleptic Treatment-Short Form (SWN-S) at Month 76 Endpoint

Patient Satisfaction With Medication Questionnaire-Modified (PSMQ) at Month 76 Endpoint

Plasma Olanzapine Concentrations in Participants During Long-Term Treatment by Year